January - 2023

NEWS

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Ymmunobio Appoints New Chief Operating Officer

Ymmunobio Accepted into Innosuisse Core Coaching

Dr. Katrin Rupalla Interviewed by Global Business Reports

Drug Discovery & Development

Fierce Biotech: Appointment of Michel Janicot

Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR antibodies

Research indicates that NPTXR may have utility for treatment of gastro-intestinal cancers. Read more here: https://www.prnewswire.com/new...

Drug Discovery & Development

Ymmunobio get ownership rights to NPTXR antibodies. Read more here: https://www.drugdiscoverytrends.com/ymmunobio-gets-ownership-rights-t...

Fierce Biotech: Appointment of Michel Janicot

Michel Janicot will serve in the newly created position of chief development officer. https://www.fiercebiotech.com/biotech/chutes-ladder...

Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer

Ymmunobio adds to executive team. Read more here: https://www.biopharmadive.com/press-release/20230109-ymmunobio-appoints-dr-michel-janic...